JP Morgan exceeds the 5% threshold at ABIVAX

JP Morgan Chase & Co. recently increased its stake in ABIVAX, exceeding the 5% voting rights threshold. This information was officially announced on October 9, 2025. As of October 6, 2025, JP Morgan indirectly held 4,376,242 shares, representing 5.65% of the company's capital and 5.12% of its voting rights.

The crossing of this threshold results from the increase in equity holdings through assimilation. Subsidiaries, such as JP Morgan Prime Inc. and JP Morgan Securities, have consolidated these holdings through various equity-like contracts and securities, including depository receipts and equity swaps exercisable between 2026 and 2030.